Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT by Strangfeld, Anja et al.
Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
http://arthritis-research.com/content/12/1/R5
Open Access RESEARCH ARTICLE
© 2010 Strangfeld et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Risk of incident or recurrent malignancies among 
patients with rheumatoid arthritis exposed to 
biologic therapy in the German biologics register 
RABBIT
Anja Strangfeld*1, Franka Hierse1, Rolf Rau2, Gerd-Ruediger Burmester3, Brigitte Krummel-Lorenz4, Winfried Demary5, 
Joachim Listing1 and Angela Zink1,3
Abstract
Introduction: We used the data of the German biologics register RABBIT, a nationwide prospective cohort study, to 
investigate the risk of new or recurrent malignancy in patients with rheumatoid arthritis (RA) receiving biologics 
compared to conventional disease modifying anti-rheumatic drugs (DMARDs).
Methods: The analysis was based on patients with RA enrolled in RABBIT at the start of a biologic or conventional 
DMARD therapy between 01 May 2001 and 31 December 2006. Incidences of first or recurrent malignancies were 
analysed separately. A nested case-control design was used to investigate the risk of developing a first malignancy. 
Matching criteria were: age, gender, follow-up time, disease activity score based on 28 joint counts (DAS28) at study 
entry, smoking status, and selected chronic co-morbid conditions (obstructive or other lung disease, kidney, liver or 
gastrointestinal disease, psoriasis).
Results: A prior malignancy was reported in 122 out of 5,120 patients. Fifty-eight of these patients had received anti-
TNFα agents, 9 anakinra, and 55 conventional DMARDs at study entry. In 14 patients (ever exposed to anti-TNFα: eight, 
to anakinra: one) 15 recurrent cancers were observed. The average time period since the onset of the first malignancy 
was nine years. Crude recurrence rates per 1,000 patient-years (pyrs) were 45.5 for patients exposed to anti-TNFα 
agents, 32.3 for anakinra patients and 31.4 for patients exposed to DMARDs only (Incidence rate ratio anti-TNFα vs. 
DMARD = 1.4, P = 0.6.). In patients without prior cancer, 74 patients (70% female, mean age: 61.3) developed a first 
malignancy during the observation. This corresponds to an incidence rate (IR) of 6.0/1,000 pyrs. Forty-four of these 
patients were ever exposed to anti-TNFα treatment (IR = 5.1/1,000 pyrs). In a nested case-control study comparing 
cancer patients to cancer-free controls, 44 of the cancer patients and 44 of the cancer-free controls were ever exposed 
to anti-TNFα agents (P = 1.0).
Conclusions: No significant differences in the overall incidence of malignancies in patients exposed or unexposed to 
anti-TNFα or anakinra treatment were found. The same applied to the risk of recurrent malignancies. However, in 
particular this last finding needs further validation in larger data sets.
Introduction
Patients with rheumatoid arthritis (RA) and other chronic
inflammatory diseases are often subject to prolonged treat-
ment with immunosuppressive drugs which modify the
immunologic pathways involved in the pathogenesis of RA.
Tumor necrosis factor alpha (TNFα) is among the cytokines
that play a major role in the inflammatory process of rheu-
matic diseases. Its inhibition leads to substantial improve-
ment in clinical signs and symptoms in a majority of
patients. To date three different agents are available as
monoclonal antibodies or receptor fusion antagonists of
TNFα. The finding that TNFα is able to induce tumor cell
apoptosis led it to be named TNF before its role in the
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inflammatory process was revealed [1]. TNFα or rather its
nuclear factor-kappa B pathway acts as an early tumor sup-
pressor [2]. This property led to concerns about a possibly
increased risk of malignancies when drugs blocking TNFα
will be used for long-term treatment.
These concerns were supported by two meta-analyses of
randomized controlled trial data. In their first aggregate
data meta-analysis of nine randomized controlled trials
(RCTs) of anti-TNFα antibody therapies (infliximab and
adalimumab) versus placebo in patients with rheumatoid
arthritis, Bongartz et al. [3] found a significantly increased
risk for malignancies in anti-TNFα versus placebo treated
patients with a pooled odds ratio of 3.3 (95% CI: 1.2 to 9.1).
In their second meta-analysis Bongartz et al. [4] found a
higher malignancy risk also in patients treated with etaner-
cept as compared to the control group, although the relative
risk estimate did not achieve statistical significance (Hazard
ratio (HR) of 1.84 [95% CI: 0.79 to 4.28]).
Considering the strict criteria for the inclusion of patients
and the thorough monitoring process preceding controlled
trials there might be an even higher risk when unselected
RA patients are treated with anti-TNFα agents in daily
rheumatologic care. Therefore, real-world data from studies
systematically observing patients treated with these agents
for long periods are of high importance.
Patients with prior malignancy are usually excluded from
participation in RCTs and most clinical recommendations
do not encourage treating these patients with anti-TNFα.
However, this treatment might be the best therapeutic
option for their inflammatory disease. Information regard-
ing the safety of biologic agents prescribed to patients with
prior malignancies is available only from two abstracts
from the British Society of Rheumatology Biologics Regis-
ter (BSRBR) [5,6], one of them indicating a possibly
increased recurrence risk for melanoma [6].
According to the national recommendations of the Ger-
man Society of Rheumatology biologic agents should be
prescribed after failure of at least six months of treatment
with two conventional DMARDs (including methotrexate
(MTX)) alone or in combination [7].
The German biologics register RABBIT is an ongoing,
nationwide prospective cohort study started in 2001 with
the approval of the first biologic agents in Germany. It was
established with the aim to assess the long-term safety of
biologic agents including TNFα blockers. Time points of
follow-up and assessments are identical for patients treated
with biologic agents and for those under therapy with con-
ventional DMARDs.
We used the data from RABBIT to investigate the fre-
quency of developing a first malignancy in patients treated
with anti-TNFα agents compared to those treated with con-
ventional DMARDs and to study the risk of patients with a
history of malignancy receiving anti-TNFα therapy.
Materials and methods
Patients
Patients aged 18 to 75 years meeting the American College
of Rheumatology (ACR) criteria for RA are eligible to be
enrolled in RABBIT at the start of treatment with a biologic
agent or a conventional DMARD after failure of at least one
other DMARD. Prior to enrollment all patients gave their
informed consent. Patients enrolled between 01 May 2001
and 31 December 2006 (end of recruitment to this cohort)
were included in the following analyses provided at least
one follow-up visit and the baseline status regarding co-
morbid conditions were available. Patients were followed
up independent of any change in their treatment regimes.
Information about patients who missed two or more consec-
utive follow-up visits was obtained by contacting the treat-
ing physicians, and if necessary the patients themselves,
their relatives or the local health authorities to determine
the patient's vital status. The reasons for dropout and the
causes of death were ascertained. Details of inclusion crite-
ria for RABBIT were previously reported [8,9]. The ethics
committee of the Charité University School of Medicine,
Berlin, approved the study protocol.
Assessments
At baseline and at predefined time points of follow-up (3, 6,
12, 18, 24, 30, 36, 48, 60 months) rheumatologists assessed
the clinical status including the components of the disease
activity score based on 28 joint counts (DAS28) and
reported treatment details and serious and non-serious
adverse events according to the International Conference on
Harmonization E2A guidelines [10]. All adverse events
were coded using the Medical Dictionary for Regulatory
Affairs (MedDRA) [11] by one of the authors (AS).
Reported malignancies were considered as events of inter-
est, and an additional query asking for diagnostic and treat-
ment details and cancer history was sent to the reporting
rheumatologist. Only in five cases we did not receive any
further information. In 50% of the cases hospital discharge
letters with the exact histopathologic results were sent to us.
At study entry rheumatologists reported co-morbidities
for every patient on a list of 23 diseases which include
among others: prior malignancy or lymphoma, chronic
obstructive pulmonary disease (COPD), other chronic lung
disease, chronic renal disease, chronic gastrointestinal dis-
ease, chronic liver disease, psoriasis, and chronic viral dis-
ease. Patients assessed their pain, general health, disability
and socioeconomic status. The Hannover Functional Status
Questionnaire (Funktionsfragebogen Hannover, FFbH) was
used to assess disability. Scores are expressed as percentage
of full function (range 0 to 100) and can be transformed into
Health Assessment Questionnaire (HAQ) values [12].
Smoking habits were not assessed at baseline but only after
24, 48, 60 months. Since this resulted in a high percentage
of missing smoking information we did not include smok-Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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ing in the multivariate analyses. Nevertheless, in the nested
case control study we were able to include smoking by
using the missing information as one matching criterion.
Statistical analysis
Prior malignancies and tumor recurrence. All patients meet-
ing the study inclusion criteria were stratified by their prior
malignancy status. For all patients prior malignancies were
reported by the rheumatologist at study entry. Patients with
or without prior malignancy were compared with respect to
patient characteristics and treatment. In patients with a
recurrent malignancy during the observation in RABBIT
we analysed whether treatment was associated with recur-
rence. We defined recurrency as development of any cancer
after a history of a prior malignancy, irrespective of the type
of the recurrent tumor.
Tumor incidence
We analysed the tumor incidence during the observation
period in all patients without prior malignancy. We included
all types of cancer except for basal cell carcinomas. One M.
Bowen was reported and included. There was no report of
other carcinomas in situ. The observed number of incident
cancers was compared with the expected number calculated
from population data [13]. Cox regression was used to anal-
yse the effects of treatment and to adjust for demographic
and clinical data. Only exposure times after enrollment in
the RABBIT register were taken into account. Patients were
considered to be exposed to anti-TNFα treatment for the
time period from the start of anti-TNFα treatment to the end
of follow-up (ever exposed-approach). The same definition
was used for anakinra exposure. Because of the applied
ever exposed-approach patients could have been exposed to
both, anti-TNFα agents and anakinra. Patients (or follow-up
time of patients) not (yet) exposed to anti-TNFα or anakinra
were considered as exposed to DMARDs only.
The following baseline characteristics were included in
the risk assessment: age, gender, disease duration, rheuma-
toid factor, functional capacity (measured by the FFbH),
selected previous treatment exposures (cyclosporine or aza-
thioprine) [14], and co-morbid conditions.
Since nearly all (98.3%) of our patients were ever
exposed to methotrexate and only a small minority (0.6%)
to cyclosphosphamide we were not able to investigate a
specific cancer risk associated with these agents. A prelimi-
nary analysis blinded for treatment assignment revealed
associations between the frequency of cancer and COPD,
chronic gastrointestinal diseases and chronic renal diseases.
Other co-morbidities, such as chronic lung diseases in gen-
eral, are known to be associated with increased cancer risk.
Therefore, the following comorbid conditions were
included in the Cox regression analysis: COPD, other
chronic lung disease, chronic renal disease, chronic gastro-
intestinal disease, chronic liver disease, and psoriasis. Fur-
thermore, we investigated the impact of exposure to anti-
TNFα agents as well as the impact of long-term high dis-
ease activity (measured by time-averaged DAS28 scores)
on the risk of cancer. For this analysis, the mean of all
DAS28 scores measured more than six months before an
event were included as time-dependent co-variables into the
Cox regression analysis. Disease activity during the six
months prior to a malignancy diagnosis was not considered
since it may have been influenced by the carcinogenesis.
For malignancies that developed within the first six months
of observation, the DAS28 measured at study entry was
used. On average 7% of the DAS28 values at follow-up
were missing. To minimize possible bias missing values
were imputed before the time-averaged scores were calcu-
lated. The expectation-maximisation (EM) algorithm most
appropriate for approximately normally distributed vari-
ables such as the DAS28 was applied for estimation and
imputation [15]. Calculations were performed using the
SAS procedures MI and PHREG. A test based on the analy-
sis of Schoenfeld residuals of Cox regression was used to
investigate the invariance of the HR over time [16].
The control for confounding factors by Cox regression
analysis may be insufficient since smoking could not be
included and two possible risk factors found in our prelimi-
nary analysis (see above) were observed in less than 5% of
the patients. Our statistical analysis plan therefore stipu-
lated to perform a nested case control study as our main
analysis of the risk of incident cancer. For each case with an
incident cancer, a cancer-free control patient was selected
who was compatible with the following matching criteria:
gender, smoking status, and six co-morbid conditions (same
as those used in the Cox regression). Cases with valid data
of smoking status were matched to controls with the same
smoking status and patients with missing information
regarding smoking status were matched to controls who
also had no smoking status data. After matching for eight
categorical variables, a control patient was selected who fit-
ted best to the case concerning age, follow-up time and
DAS28 at baseline. Standardized Mahalanobis metric was
used for measuring similarity. The availability of 4,923 pos-
sible controls permitted use of this detailed matching algo-
rithm. Mc Nemar test was used to compare the numbers of
patients exposed to biologics (anti-TNFα agents or anak-
inra) between patients and matched controls. For further
comparisons within the nested case control study, paired t-
test and Wilcoxon test were applied as appropriate. Chi-
square test, t-test and Mann-Whitney test were used for sta-
tistical comparisons of patient's characteristics at baseline.
P-values < 0.05 were considered statistically significant.
Results
Patient characteristics and treatment status at study entry
Between 01 May 2001 and 31 December 2006, 5,279
patients were enrolled in RABBIT. One hundred fifty-nine
patients were excluded from this analysis because of miss-Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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ing follow-up information or missing co-morbid condition
status (Figure 1). Their baseline characteristics (age,
DAS28, function, co-morbidity status) were not statistically
different from the remaining 5,120 patients. Those were
stratified according to their prior malignancy status, and
both groups were analysed separately. A total of 124 prior
malignancies were found in 122 patients: 6 lymphomas
(DMARDs: 2, anti-TNFα: 4), and 118 solid tumors
(DMARDs: 54, anakinra: 9, anti-TNFα: 55)]. Patients with
prior malignancies were significantly older (P < 0.001), had
a lower functional capacity (56% of full function vs. 60%
of full function) and a higher frequency of chronic gastroin-
testinal disease than patients without prior malignancy
(Table 1). Within both strata, we found that patients receiv-
ing biologics had significantly more active disease, and
were more limited in activities of daily living (FFbH). As
reported previously, there were no significant differences in
the clinical characteristics of patients receiving etanercept,
adalimumab, or infliximab [17], whereas anakinra patients
had more treatment failures with DMARDs and a lower
functional capacity (FFbH) than anti-TNFα patients.
Because of the differing modes of action and the differences
in the clinical characteristics, separate results are provided
in the following analyses for patients receiving anti-TNFα
agents and patients receiving anakinra.
Patients with a prior malignancy were insignificantly less
frequently treated with anti-TNFα agents or anakinra at
inclusion than patients without prior malignancy (Figure 1,
Table 1). The adjusted OR to receive biologics (adjusted for
age, sex, disability, disease activity) for patients with prior
malignancies compared to those without was 0.7 (95%CI:
0.5 to 1.1). Detailed information including the exact type of
malignancy was reported in 54 of the 124 prior malignan-
cies. We found some differences regarding the spectrum of
those malignancies in anti-TNFα vs. DMARD treated
patients: At study entry all nine cases with prior prostatic
Figure 1 Flow chart of patients included in the analysis.
Patients enrolled in 
RABBIT:   n = 5279 
No follow-up data:   
n = 155 
n = 5124 
Missing co-morbid 
condition status:  
n = 4 
n = 5120 
Prior malignancies  
n = 122 
Without prior malignancies   
n = 4998 
Conventional 
DMARD: n = 1719 
Biologics n = 3279 
etanercept: n = 1220 
adalimumab: n = 1398 
infliximab: n = 584 
anakinra: n = 77 
Biologics n = 67 
etanercept: n = 28 
adalimumab: n = 24 
infliximab: n = 6 
anakinra: n = 9 
Conventional 
DMARD: n = 55 S
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Table 1: Baseline characteristics of patients
Patients with prior malignancy Patients without prior malignancy
Biologic Control Total P # Biologic Control Total P # P ##
n 67 55 122 3279 1719 4998
Female n (%) 45 (67.2) 41 (74.5) 86 (70.5) 0.43 2564 (78.2) 1353 (78.7) 3917 (78.4) 0.671 0.047
Age (mean, SD) 64.0 (9.0) 63.2 (7.7) 63.7 (8.4) 0.62 53.6 (12.3) 55.9 (11.5) 54.4 (12.1) < 0.0001 < 0.001
Disease duration 
(yrs), median (IQR)
10 (6, 16.5) 7 (3, 13) 9 (4, 16) 0.02 9 (5, 17) 6 (2.5, 12) 8 (4, 15) < 0.0001 0.286
Time from prior 
cancer to study 
entry (yrs), median 
(IQR)
5 (2, 9) 5 (3, 11) 5 (2, 10) 0.77
Follow-up time 
(yrs), median (IQR)
2.1 (1.4, 3.0) 2.5 (1.0, 4.0) 2.1 (1.1, 3.1) 0.43 2.4 (1.4, 3.1) 2.5 (1.3, 3.3) 2.4 (1.3, 3.1) 0.081 0.611
Rheumatoid factor 
positive n (%)
53 (79.1) 46 (83.6) 99 (81.1) 0.64 2629 (80.2) 1225 (71.3) 3854 (77.1) < 0.0001 0.327
DAS28 (mean, SD) 5.7 (1.3) 5.4 (1.1) 5.6 (1.2) 0.04 5.8 (1.3) 5.0 (1.3) 5.5 (1.3) < 0.0001 0.282
ESR (mm/h), median 
(IQR)
38 (18, 51) 26 (15, 42) 32 (17, 50) 0.12 30 (16, 48) 22 (12, 38) 27 (14, 44) < 0.0001 0.080
CRP (mg/L), median 
(IQR)
25 (10, 46) 15 (8, 30) 19 (9, 43) 0.07 17 (8, 38) 12 (5, 27) 15 (7, 34) < 0.0001 0.146
FFbH (mean, SD) 52.1 (21.3) 59.9 (23.5) 55.7 (22.5) 0.02 57.0 (23.0) 66.8 (21.4) 60.4 (22.9) < 0.0001 0.025
Smoking ever n (%) 23 (57.5) 15 (55.6) 38 (56.7) 1.00 878 (46.9) 473 (46.4) 1351 (46.7) 0.328 0.13
No. of previous 
DMARDs (mean, SD)
3.7 (1.5) 1.9 (1.0) 2.9 (1.6) < 0.001 3.6 (1.4) 1.9 (1.1) 2.9 (1.5) < 0.0001 0.656
COPD n (%) 3 (4.4) 6 (10.9) 9 (7.3) 0.30 163 (5) 81 (4.7) 244 (4.9) 0.685 0.205
Chronic renal 
disease n (%)
4 (5.9) 1 (1.8) 5 (4.1) 0.38 134 (4.1) 29 (1.7) 163 (3.3) < 0.0001 0.603
Chronic lung 
disease n (%)
5 (7.4) 1 (1.8) 6 (4.9) 0.22 93 (2.8) 29 (1.7) 122 (2.4) 0.012 0.129
Chronic 
gastrointest. 
disease n (%)
12 (17.6) 5 (9.1) 17 (13.9) 0.2 281 (8.6) 138 (8.0) 419 (8.4) 0.510 0.047
Values are means and standard deviations if not otherwise specified. IQR = inter quartile range; FFbH = Hannover Functional Status Questionnaire measuring functional capacity in percent of full function; DAS28: 
disease activity score based on 28 joint counts;
# = P-value for comparison between biologic and control group within strata according to prior malignancy status, ## = comparison between strataStrangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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cancer were treated with biologics (seven with anti-TNFα
and two with anakinra) whereas three patients with prior
bladder cancer were found in the DMARD treated group
and one patient was treated with anakinra. Patients with
prior breast cancer were less frequently treated with biolog-
ics (n = 11) than with DMARDs (n = 14) at inclusion. The
time between onset of the prior malignancy and study entry
did not differ between the treatment groups. The median
time was five years (IQR: 2 to 9) for patients receiving bio-
logics (anti-TNFα: four years (2 to 10); anakinra: six years
(5 to 9)) and five years (3 to 11) for patients receiving con-
ventional DMARDs (P  = 0.77). In 28 (45.9%) of the
patients treated with biologics (27 with anti-TNFα and 1
with anakinra) and in 22 (40.7%) patients in the DMARD
group the time since the last tumor diagnosis was less than
five years when treatment with the respective agent started.
Recurrence of a prior malignancy
During follow-up 15 recurrent cancers were observed in 14
patients including 14 recurrences of the same type and site
as the prior tumor and one metastasis of unknown origin
(Table 2). Nine recurrences were seen in eight patients
under treatment with anti-TNFα agents, one in an anakinra
patient and five in patients exposed to DMARDs only. The
corresponding crude incidence rates were 45.5 (95%CI:
20.8 to 86.3)/1,000 patient years (pyrs) for patients receiv-
ing anti-TNFα agents, 32.3 (95%CI: 0.8 to 179.7)/1,000
pyrs for patients treated with anakinra and 31.4 (95%CI:
10.2 to 73.4)/1,000 pyrs for DMARD treated patients (inci-
dence rate ratio anti-TNFα agents vs. DMARDs: 1.4 (95%
CI: 0.5 to 5.5) P = 0.63).
The mean time span between the prior tumor and the
diagnosis of the new tumor was 9.5 (SD: 7.8), 9.1, and 9.2
(8.8.) years for patients exposed to anti-TNFα agents, anak-
inra, or conventional DMARDs, respectively. Three
patients developed a recurrent cancer less than five years
after the previous cancer (two in the anti-TNFα treated
group, one in the DMARD group).
Four of the five patients who were treated with conven-
tional DMARDs only and experienced a recurrence of their
prior malignancy died (signet-ring-cell carcinoma, metasta-
sis of unknown origin, breast cancer, lung cancer). One out
of the eight patients under treatment with anti-TNFα died
(breast cancer), and the one patient under treatment with
anakinra (lung cancer) died. All other patients with recur-
rences were still alive at the time of the analysis.
Incidence of tumors in patients without a prior malignancy
Comparison of the tumor incidence with the general 
population
Seventy-four patients among the 4,998 patients who did not
have a prior malignancy developed an incident tumor. This
is an overall incidence rate of 6.0 per 1,000 pyrs [95% CI:
4.7 to 7.6]. The figures were 5.1 per 1,000 pyrs (95% CI:
3.7 to 6.9) for patients exposed to anti-TNFα, 7.2 per 1,000
pyrs (95% CI: 2.4 to 16.9) for patients exposed to anakinra
and 8.4 per 1,000 pyrs (95% CI: 5.7 to 12.0) for patients
exposed to conventional DMARDs. For some of the cancer
sites the observed incidence rates in both groups were lower
than the age and sex adjusted rates as expected from the
general population (for example, breast, male and female
reproductive organs and colon cancer) [13] (Figure 2).
Higher rates were observed for non-Hodgkin's lymphoma
in patients exposed to biologics and for pancreatic cancer in
the group not exposed to biologics. None of the site specific
differences were statistically significant when the P-values
were adjusted for repeated significance testing. Taking into
account all malignancies, the number of observed cancers
in patients exposed to anti-TNFα agents was non-signifi-
cantly lower than the expected number from the general
population (standardized incidence rate ratio: 0.75, 95% CI:
0.54 to 1.01). No difference was found for patients not
exposed to biologics.
Comparison of patients with and without incident tumors in 
patients with no prior cancer
Overall, patients who developed malignancies during the
study period had more co-morbidities than those who did
not (mean = 2.5 (SD = 2.1) vs. 1.7(1.9)). Higher rates were
observed for COPD (11/74 (14.9%) vs. 223/4924 (4.5%), P
< 0.0001), chronic gastrointestinal diseases ((13/74 (17.6%)
vs. 406/4924 (8.2%), P = 0.008), and chronic renal diseases
(4/74 (5.4%) vs. 159/4924 (3.2%), P = 0.22). Furthermore,
site specific associations were observed for gastric/colorec-
tal cancer in 2/419 patients with a chronic gastrointestinal
disease vs. 3/4579 in the remaining patients (P = 0.06), and
for bladder cancer/renal cancer in 1/163 patients with
chronic renal diseases vs. 3/4835 in the remaining patients
(P = 0.12).
Crude cancer incidence rates were therefore higher in
patients with specific comorbid conditions but also in those
with a highly active disease (Table 3).
The univariate analysis showed that patients with a very
active disease (DAS28 >5.1, mean: 5.93) during follow-up
had a two times higher cancer risk than those with low dis-
ease activity (DAS28 <3.2, mean: 2.75) (Table 4).
In the multivariate analysis the development of an inci-
dent tumor was strongly associated with age (HR = 1.71;
95% CI: 1.3 to 2.2 per 10 years increase in age, P < 0.0001)
and COPD (HR = 2.63; 95% CI: 1.4 to 5.0, P = 0.004)
(Table 4). A higher cancer risk was also observed for
patients with chronic gastrointestinal diseases whereas no
significant associations were found for other co-morbid
conditions (other chronic lung diseases, psoriasis, chronic
liver disease) or for gender (HR (males vs. females) = 1.46;
95% CI: 0.9 to 2.4, P = 0.14). Likewise, associations for
patients ever exposed to cyclosporine (n = 582, P = 0.24) or
azathioprine (n = 599, P = 0.32) were not statistically sig-
nificant.Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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In patients exposed to anti-TNFα agents we observed a
non-significantly decreased risk for developing a malig-
nancy compared to patients treated with conventional
DMARDs (adjusted HR = 0.70; 95% CI: 0.44 to 1.12, P =
0.13).
Time dependency of the hazard risk in patients without 
prior cancer
The mean time until the onset of the malignancy was 25.0
(16.8) months for patients exposed to anti-TNFα agents,
14.8 (9.1) for anakinra and 17.4 (15.7) months for patients
not exposed to biologics. Ten of the 44 malignancies of
anti-TNFα-exposed patients developed in the first year
compared to 15 of 30 malignancies in non-exposed
patients. This corresponds to adjusted hazard ratios of 0.4
for the first and 1.0 for the second to fourth year. We analy-
sed this possible time trend in the hazard ratio by means of
an analysis of standardized Schoenfeld residuals of the Cox
regression. The trend was, however, not statistically signifi-
cant (P = 0.13).
Nested case-control study
The main analysis to assess the risk of developing an inci-
dent tumor under treatment with anti-TNFα agents was
conducted as a nested case control study. Each case with an
incident malignancy was matched to one control patient
without malignancy (see Methods). Due to the high number
of possible matching partners, matching was successful for
all parameters involved. Cases with incident malignancy
had lower baseline functional capacity than those without
cancer (Table 5). There was no significant difference con-
cerning treatment exposure: Forty-four (59.5%) of the cases
and 45 (60.8%) of the controls had ever been exposed to
biologics. The numbers of cases ever exposed to etanercept,
adalimumab, infliximab, or anakinra (n = 22; n = 20; n =
16; n = 5, respectively) did not differ significantly from the
numbers of controls ever exposed to these therapies (n = 27;
n = 24; n = 10; n = 5, respectively). A separate analysis of
malignancies observed in the first year (anti-TNFα exposed
10/25 cases vs. 11/25 controls) and in the second to fourth
year (anti-TNFα exposed: 34/49 cases vs. 33/49 controls)
did not show any significant difference between the groups
or a significant time trend.
An insignificantly higher rate of exposure to anti-TNFα
agents was found in patients who developed non-Hodgkin's
lymphoma.
Discussion
First, in patients with prior malignancy we did not find a
significant increase in the risk of recurrent tumors under
treatment with anti-TNFα agents compared to conventional
DMARDs, even though there was a higher recurrence rate
under anti-TNFα treatment (IRR = 1.4, P = 0.6).
Table 2: Recurrence of prior malignancy by type and treatment
Ever exposed to
Total Anti-TNFα Anakinra Conventional 
DMARD only
N with prior 
malignancy
1 2 2 7 21 14 3
Patient-years of 
follow-up
379 198 31 159
Recurrent 
malignancies
15 9 (5 f, 4 m) 1 (m) 5 (4 f, 1 m)
Breast cancer 54  ( f )- 1 ( f )
Lung cancer 3 1 (m) 1 (m) 1 (f)
Bladder cancer 21  ( m ) # -1  ( f )
Liposarcoma 11  ( m )- -
Melanoma 11  ( f )
Signet-ring cell 
carcinoma
1-- 1  ( f )
Testicular cancer 11  ( m ) # --
Metastasis 
of unknown 
origin
1 1 (m)
M = male, f = female, #testicular cancer and bladder cancer in one patientStrangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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Second, patients without prior malignancy did not have
higher rates of incident tumors when they were exposed to
biologics compared to unexposed patients.
The strength of our study is that all data on incident and
recurrent tumours originate from a prospective, closely
monitored observational cohort study established for the
purpose of pharmacovigilance. Data were collected in an
identical manner and by the same physicians for patients
treated with biologic agents or with conventional
DMARDs. Due to stringent and close monitoring, drop-out
rates were less than 5% per year. Additionally, for all
patients lost to follow-up the vital status was ascertained or,
if appropriate, the cause of death.
To investigate the occurrence of incident malignancies,
we followed three different methodological approaches: a
nested case-control study, a multivariate Cox regression and
a comparison with population data.
Of note, we excluded basal cell carcinoma from all types
of our analysis since no age and sex specific population
rates were available.
The design of the nested case control study allowed us to
adjust for differences in clinical and demographic parame-
ters (for example, selected co-morbidities, smoking status)
which are related to treatment assignment but which are
also associated with the risk of cancer. We therefore con-
sider the nested-case control analysis our central assess-
ment of the risk of incident malignancies under treatment
with anti-TNFα agents. However, since only a very small
proportion of the patients were included in the nested case
control analysis and therefore information of a large num-
ber of patients was not used, we decided to apply a multi-
variate Cox regression analysis in addition.
A potential weakness of this study is that we only investi-
gated the overall cancer risk. The risk for site-specific can-
cers has not been analyzed due to the limited numbers of
events. In addition, due to the relatively short time of obser-
vation no conclusions can be drawn beyond the scope of
four years of exposure.
Limitations of the analysis of tumor recurrence include
the relatively small sample size and the fact that physicians
were less likely to prescribe cytokine inhibitors for patients
with prior malignancy than for those without such a history.
Furthermore, our data indicate that physicians might have
made different treatment decisions for patients with differ-
ent prior tumors. We therefore must exhibit caution in
drawing firm conclusions.
The same applies for the interpretation of the data for
anakinra treated patients: only a few patients in the cohort
were ever treated with anakinra, most of them were also
exposed to anti-TNFα agents. Therefore, malignancies
occurring in this group must be interpreted carefully, taking
patient selection (also seen in differing baseline characteris-
tics) into account.
Our results differ from those reported by the British Soci-
ety for Rheumatology Biologics Registry (BSRBR) [6].
Dixon and co-workers analyzed 177 patients with prior
malignancies treated with anti-TNFα agents with a median
follow-up of three years and found no increased risk for
recurrent malignant diseases compared to 118 patients with
prior malignancies treated with conventional DMARDs and
followed-up for 1.9 years. Their crude incidence rates were
25.3 and 41.9 per 1,000 patient-years for patients treated
with anti-TNFα agents and conventional DMARDs, respec-
tively, compared to 45.5 and 31.4 per 1,000 patients-years
in our study. In an earlier analysis of the BSRBR [5] a total
of 154 patients in the anti-TNFα cohort had a previous
malignancy and six (4%) developed a new malignancy.
However, of these malignancies only one was a local recur-
rence which is in contrast to our findings. In our study, in 14
out of the 15 recurrences the observed malignancies were
true recurrences of the prior tumor with the same type and
site. Only in one of our patients with pulmonary and bone
metastases the origin of the malignancy remained
unknown. This patient had a history of testicular cancer 20
years before.
Our investigations regarding the risk of developing an
incident malignancy were motivated by two meta-analyses
of randomized controlled trials which suggested an
Figure 2 Observed numbers of cancers and expected numbers 
from the general population, standardized by age and sex.Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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increased risk of malignancies associated with the treatment
with one of the TNFα blocking agents: adalimumab, inflix-
imab, or etanercept [3,4]. The results of these meta-analy-
ses are in contrast with those from observational cohort
studies or national cancer registries, in which such an
increased risk was not observed [18,19]. The methodologi-
cal weaknesses of the first meta-analysis investigating the
risk for treatment with adalimumab or infliximab have
already been discussed elsewhere [20]. However, the
repeated finding of an increased cancer risk also in patients
treated with etanercept [3,4] requires further research, even
if it did not achieve statistical significance. These meta-
analyses support the early mobilization hypothesis implying
a high risk within the first months of treatment with anti-
TNFα agents.
However, our results for the first year are in contrast to
the meta-analyses reported by Bongartz et al. [3,4]. In the
first year of treatment patients receiving biologics had a
lower risk for developing an incident malignancy than those
Table 3: Crude incidence rates of malignancies
n of CA n pyrs IR
Characteristics at 
baseline
Age (per 10 yrs 
increase)
Female 52 3,917 9,687 5.4
Male 22 1,081 2,554 8.6
Co-morbid conditions:
COPD
No 63 4,754 11,677 5.4
Yes 11 244 564 19.5
Gastrointestinal 
disease
No 61 4,579 11,153 5.5
Yes 13 419 1,088 11.9
Renal disease
No 70 4,835 11,884 5.9
Yes 4 163 357 11.2
Characteristics at 
follow-up
DAS28
<3.2 6 787 2,165 2.8
3.2 to 5.1 34 2,823 7,341 4.6
>5.1 34 1,388 2,735 12.4
Ever exposed to
Conventional DMARDs 
only
30 1,684 # 3,561 8.4
Anti-TNF agents 44 3,651 * 8,558 5.1
Anakinra 5 247 $ 690 7.2
CA: malignancies, n = number of cases, pyrs = follow-up time in patient years, IR = crude incidence rate per 1,000 pyrs.
#35 of the patients in the DMARD cohort were exposed to anti-TNF agents before inclusion in the study. According to the ever exposed 
approach their follow-up time was assigned to the anti-TNF treated group.
* Patients included in this group are patients who were included in the study with the start of an anti-TNF agent (n = 3,201) and patients who 
changed during follow-up from DMARD or anakinra treatment to anti-TNF treatment
$223 of the 247 pts were exposed to anakinra and anti-TNF agents, they experienced five malignancies.Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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receiving conventional DMARDs. This may be due to a
selection bias evoked by the screening process for malig-
nancies following the physician's decision that a patient
should receive biologic treatment. Screening for latent TB
by chest x-ray as recommended in guidelines [21] may
reveal asymptomatic lung cancers and only those patients
who screen negative for current malignancies will receive
biologic treatment and be included in the biologics group in
the RABBIT register. No such general screening occurs in
patients who will receive a new DMARD therapy. There-
fore the rate for malignancies in the DMARD group repre-
sents the true unselected rate that can be expected for RA
patients under conventional DMARD treatment. Indeed this
concept is supported by our findings that the observed num-
ber of cancer cases in the DMARD treated group (n = 30)
was equal to the expected number (n = 30.8), whereas the
observed number in the biologics group (n = 44) was lower
than what would have been expected based on the rates
from the general population (n = 64.3).
In contrast to an increased risk, it is also possible that
inhibition of TNFα has beneficial or even preventive effects
regarding cancer. TNFα is important in all steps of cancer
development, for example, initiation, promotion, and sur-
vival. Elevated levels of TNFα are linked to a poor progno-
sis and increased invasiveness in certain human cancers
[22,23]. However, the results of first trials to treat breast or
ovarian cancer with TNFα inhibitors have been, so far,
inconclusive [24,25]. The increased risk of non-Hodgkin's
lymphoma in RA patients treated with biologic agents is
well established [26,27] and has been shown to be strongly
associated with long-term high disease activity [28] which
is more likely in the history of patients subsequently treated
with biologic agents. Nevertheless, in our nested case con-
trol study where we controlled for disease activity and dura-
tion we still found a higher proportion of anti-TNFα
Table 4: Hazard ratios of developing a malignancy
Univariate Cox regression Multivariate analysis
HR 95% CI P adjusted HR 95% CI P
Characteristics at 
baseline
Age (per 10 yrs 
increase)
1.82 1.44 to 2.31 < 0.0001 1.71 1.35 to 2.17 < 0.0001
Male vs. female 1.61 0.98 to 2.65 0.062 1.47 0.89 to 2.43 0.13
Co-morbid 
conditions:
COPD 3.64 1.92 to 6.91 < 0.0001 2.63 1.37 to 5.04 0.004
Gastrointestinal 
disease
2.19 1.20 to 3.98 0.010 1.81 0.99 to 3.30 0.0534
Renal disease 1.93 0.70 to 5.28 0.20
Characteristics at 
follow-up
DAS28 (per unit 
increase)
1.24 1.02 to 1.50 0.034
DAS28
< 3.2 Referent
3.2 to 5.1 1.28 0.54 to 3.06 0.58
> 5.1 2.00 0.82 to 4.86 0.13
Ever exposed to
Conventional 
DMARDs only
Referent Referent
Anti-TNF agents 0.61 0.39 to 0.97 0.039 0.70 0.44 to 1.12 0.133
Anakinra 1.16 0.47 to 2.89 0.75 1.39 0.56 to 3.48 0.480Strangfeld et al. Arthritis Research & Therapy 2010, 12:R5
http://arthritis-research.com/content/12/1/R5
Page 11 of 13
Table 5: Patient characteristics of cases and matched controls
Cases
(with incident malignancy)
Matched controls P
N7 4 7 4
Characteristics at study entry
Females# n (%) 52 (70.3) 52 (70.3) n.a.
Age# (mean, SD) 61.3 (8.9) 61.4 (8.5) 0.97
Observation time# (years) 
(median, IQR)
2.9 (1.8, 4.0) 2.9 (1.6, 3.9) 0.25
DAS28# (mean, SD) 5.6 (1.0) 5.7 (1.0) 0.31
Smoking status#
Nonsmoker 16 (21.6) 16 (21.6) n.a.
Smoker n (%) 19 (25.7) 19 (25.7)
Unknown status n (%) 39 (52.7) 39 (52.7)
Disease duration (years) (median, 
IQR)
7 (3,14) 9 (5,16) 0.22
Functional status, FFbH (mean, 
SD)
57.1 (22.3) 63.2 (22.6) 0.058
Characteristics at follow-up
DAS28 (mean, SD)$ 5.0 (1.2) 4.9 (1.2) 0.41
Ever exposed to biologics n 
(%)
44 (59.5) 45 (60.8) 1.0
Ever exposed to anti-TNFα 
agents &
44 (59.5) 44 (59.5) 1.0
Ever exposed to anakinra& 5 (6.8) 5 (6.8) 1.0
Among them
Cases with solid tumors (n = 68)
Ever exposed to biologics 39 (57.4) 43 (63.2) 0.56
Ever exposed to anti-TNFα 
agents
39 (57.4) 42 (61.8) 0.70
Ever exposed to anakinra 5 (7.4) 5 (7.4) 1.0
Cases with non-Hodgkin's 
Lymphoma (n = 6)
Characteristics at study entry
Females# n(%) 5 (83.3) 5 (83.3) n.a.
Age# (mean, SD) 65.2 (6.5) 66.8 (8.0) 0.13
Disease duration 5.5 (4,13) 7 (5,11) 0.53
Functional status, FFbH (mean, 
SD)
52.8 (31.4) 54.2 (27.5) 0.90
DAS28# (mean, SD) 5.9 (0.6) 6.2 (0.5) 0.29
Characteristics at follow-up
DAS28 (mean, SD)$ 5.2 (0.7) 5.5 (0.7) 0.14
Ever exposed to anti-TNFα 
agents
5 (83.3) 2 (33.3) 0.38
# matching criteria (further matching criteria not shown in the table = COPD, other chronic lung disease, chronic renal disease, chronic gastrointestinal 
disease, chronic liver disease, and psoriasis)
&five cases and four controls received anti-TNFα agents and anakinra (at different points in time)
$cases = mean of DAS28 values over time points until six months prior to the cancer diagnosis, matched controls: mean of DAS28 values over time points 
of the corresponding caseStrangfeld et al. Arthritis Research & Therapy 2010, 12:R5
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exposure in patients with incident non-Hodgkin's lympho-
mas vs matched controls. This difference was not found for
solid tumors.
Conclusions
Our data add to the growing evidence of no overall
increased cancer risk for patients treated with anti-TNFα
agents during the first years of treatment. This does not pre-
clude that there may be an increased risk for specific cancer
types such as lymphoma or skin cancer.
Taking the limitations of the currently available evidence
into account there is a need for further large-scale prospec-
tive studies investigating risk modifications for different
cancer sites as well as investigating the cancer risk after
long-term exposure to biologic agents above four years.
Further, this study provides first but limited evidence
regarding the risk of patients with a prior malignancy
treated with anti-TNFα agents. The finding of an insignifi-
cantly increased risk of recurrence under anti-TNFα treat-
ment supports the current practice of carefully balancing
treatment decisions in these patients.
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